文献速递脊柱关节炎

比奇珠单抗治疗中轴型脊柱关节炎的疗效与安全性比较:系统文献综述与网状Meta分析

Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该系统文献综述与网状Meta分析纳入36项随机对照试验,比较比奇珠单抗160 mg每4周一次与生物/靶向合成改善病情抗风湿药在中轴型脊柱关节炎中的疗效与安全性;在 predominantly-naïve 网络中,比奇珠单抗在非放射学中轴型脊柱关节炎和强直性脊柱炎的部分ASAS结局上优于司库奇尤单抗150 mg,与大多数其他b/tsDMARDs相当,安全性相似。

要点

  • 在 predominantly-naïve 非放射学中轴型脊柱关节炎分析中,比奇珠单抗的ASAS20应答率显著高于司库奇尤单抗150 mg(含负荷剂量/不含负荷剂量),与其他活性对照相当。
  • 在 predominantly-naïve 强直性脊柱炎分析中,比奇珠单抗的ASAS40应答率显著高于司库奇尤单抗150 mg(不含负荷剂量),ASAS-PR应答率显著高于司库奇尤单抗150 mg(含负荷剂量)。
  • 比奇珠单抗在12-16周的安全性与其它b/tsDMARDs相似。

核心结论

  • 在ASAS结局上,比奇珠单抗与大多数b/tsDMARDs(包括依奇珠单抗、TNF抑制剂和乌帕替尼)相当,并在 predominantly b/tsDMARD-naïve 的非放射学中轴型脊柱关节炎和强直性脊柱炎患者中,于12-16周时对部分ASAS结局的应答率高于司库奇尤单抗。
  • 在汇总的中轴型脊柱关节炎网络中,比奇珠单抗与其他b/tsDMARDs的安全性相当。

研究设计与样本

  • 系统文献综述检索截至2023年1月的随机对照试验,纳入贝叶斯网状Meta分析,包括三个b/tsDMARDs暴露网络:predominantly-naïve、naïve和experienced。
  • 网状Meta分析共纳入36项试验。
  • 疗效结局为12-16周时的ASAS20、ASAS40和ASAS部分缓解(PR)应答率;安全性网状Meta分析探讨12-16周时因任何原因停药和严重不良事件。

主要发现

  • 在 predominantly-naïve 非放射学中轴型脊柱关节炎分析中,比奇珠单抗的ASAS20应答率显著高于司库奇尤单抗150 mg(含负荷剂量/不含负荷剂量),与其他活性对照的应答率相当。
  • 在 predominantly-naïve 强直性脊柱炎分析中,比奇珠单抗的ASAS40应答率显著高于司库奇尤单抗150 mg(不含负荷剂量),ASAS-PR应答率显著高于司库奇尤单抗150 mg(含负荷剂量),与其他活性对照的应答率相当。
  • 比奇珠单抗的安全性与其他b/tsDMARDs相似。

关键数值与推荐

  • 比奇珠单抗160 mg每4周一次,为IL-17F和IL-17A选择性抑制剂。
  • 疗效结局为12-16周时的ASAS20、ASAS40和ASAS部分缓解应答率。
  • 安全性结局为12-16周时因任何原因停药和严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the efficacy and safety of bimekizumab 160 mg every 4 weeks, a selective inhibitor of IL-17F and IL-17A, with those of biologic/targeted synthetic DMARDs (b/tsDMARDs) in non-radiographic axial SpA (nr-axSpA) and AS. METHODS: A systematic literature review identified randomized controlled trials until January 2023 for inclusion in Bayesian network meta-analyses (NMAs), including three b/tsDMARDs exposure networks: predominantly-naïve, naïve, and experienced. Outcomes were Assessment of SpondyloArthritis international Society (ASAS)20, ASAS40 and ASAS partial remission (PR) response rates at 12-16 weeks. A safety NMA investigated discontinuations due to any reason and serious adverse events at 12-16 weeks. RESULTS: The NMA included 36 trials. The predominantly-naïve network provided the most comprehensive results. In the predominantly-naïve nr-axSpA analysis, bimekizumab had significantly higher ASAS20 response rates vs secukinumab 150 mg [with loading dose (LD)/without LD], and comparable response rates vs other active comparators. In the predominantly-naïve AS analysis, bimekizumab had significantly higher ASAS40 response rates vs secukinumab 150 mg (without LD), significantly higher ASAS-PR response rates vs secukinumab 150 mg (with LD) and comparable response rates vs other active comparators. Bimekizumab demonstrated similar safety to that of other b/tsDMARDs. CONCLUSION: Across ASAS outcomes, bimekizumab was comparable with most b/tsDMARDs, including ixekizumab, TNF inhibitors and upadacitinib, and achieved higher response rates vs secukinumab for some ASAS outcomes in predominantly b/tsDMARD-naïve nr-axSpA and AS patients at 12-16 weeks. In a pooled axSpA network, bimekizumab demonstrated comparable safety vs other b/tsDMARDs.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Deodhar A, Machado PM, Mørup M, et al. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2024. PMID: 37947318. doi:10.1093/rheumatology/kead598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。